Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Debt to Equity (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Debt to Equity for 7 consecutive years, with -$0.55 as the latest value for Q2 2025.

  • Quarterly Debt to Equity changed N/A to -$0.55 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$0.55 through Jun 2025, changed N/A year-over-year, with the annual reading at -$0.42 for FY2019, 6379.6% down from the prior year.
  • Debt to Equity for Q2 2025 was -$0.55 at Outlook Therapeutics, up from -$0.65 in the prior quarter.
  • The five-year high for Debt to Equity was -$0.55 in Q2 2025, with the low at -$0.65 in Q1 2025.